Table 2 Immunological discordant responses and associated factors among HAART users in Mekelle Hospital and Ayder Comprehensive Specialized Hospital (n = 260)
Characteristics | Immunological discordance | P-value* |
|---|---|---|
Yes n (%) | Â | |
Gender | ||
 Male | 3 (2.8) | 1.000 |
 Female | 4 (2.6) | |
Age (years) at HAART initiation | ||
 < 35 | 2 (2.4) | 1.000 |
 > 35 | 5 (2.8) | |
Age (years) at 36 months median time of HAART follow up | ||
 < 39 | 3 (2.1) | 0.706 |
 > 39 | 4 (3.4) | |
Residence | ||
 Rural | 1 (2.0) | 1.000 |
 Urban | 6 (2.8) | |
Chronic non-communicable diseasesa | ||
 Yes | 0 (0) | 1.000 |
 No | 72.8) | |
TB co-infection | ||
 Yes | 4 (9.3) | 0.016 |
 No | 3 (1.4) | |
History of Opportunistic Infections (other than TB)b | ||
 Yes | 3 (2.1) | 0.704 |
 No | 4 (3.4) | |
HBV co-infection | ||
 Yes | 2 (18.2) | 0.05 |
 No | 3 (2.8) | |
HCV co-infection | ||
 Yes | 1 (50.0) | 0.062 |
 No | 1 (1.6) | |
Adherence to treatment | ||
 Poor/fair | 2 (11.1) | 0.08 |
 Good | 5 (2.1) | |
WHO clinical stage at baseline | ||
 I and II | 0 (0.0) |  |
 III and IV | 7 (5.1) |  |
CD4+ count (cell/μl) at baseline | ||
 < 100 | 5 (6.5) | 0.026 |
 > 100 | 2 (1.1) | |
Regimen given | ||
 TDF basedc | 7 (3.6) |  |
 AZT basedd | 0 (0) |  |